Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 15 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back ('relapsed') or does not respond to therapy ('refractory'). This study involves taking a drug called uproleselan that is not yet approved for use in children or adults. The purpose of the study is to find a safe dose of the study drug in children that can be given with standard chemotherapy without causing severe side effects. 

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT05146739

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
22-020565
Official Title:
PEPN2113: A Phase 1 and pharmacokinetic study of Uproleselan (GMI-1271, IND #139758, NSC #801708) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia, myelodysplastic syndrome or mixed phenotype acute leukemia that expresses E-selectin ligand on the cell membrane and is in second or greater relapse or that is refractory to relapse therapy
Study Phase:
Phase I
Eligible Age Range:
0 - 17 Years
Gender:
All
Study Categories:

Visit Criteria

As a participant in the research, you will:

  • Receive a study drug called uproleselan
  • Complete frequent clinic visits at CHOP
  • Have frequent blood tests
  • Have periodic electrocardiograms (ECGs) and echocardiograms (ECHOs) as part of your regular cancer care
  • Have extra or leftover tissue collected if you have a bone marrow biopsy as part of your regular cancer care
  • Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
Leader